SCIENTIFIC PROGRAMME
Thursday, March 21, 2024
08.30 Registration Opens
​
09.30 - 09.40 Welcome Address
Michael von Bergwelt, Munich, Germany
​
09.40 - 11.10 Plenary Session 1: Basic Tumor Immunology
Chair: Sebastian Kobold, Munich, Germany & Niroshana Anandasabapathy, New York, NY, USA
09.40 - 10.10
01.01. Tissue resident macrophages and cancer
Julie Helft, Paris, France
10.10 - 10.40
01.02. Nociception and cancer immunosurveillance
Sebastien Talbot, Kingston, ON, Canada
10.40 - 11.10
01.03. Understanding T cell metabolism to improve cancer immunotherapy
Mathias Wenes, Geneva, Switzerland
​
11.10 - 11.40 Coffee Break
​
11.40 - 13.10 Plenary Session 2: New Targets and New Leads
Chair: Jose Saro, Plan-Les-Ouates, Switzerland & Pedro Romero, Lausanne, Switzerland
​
11.40 - 12.10
02.01. Type I IFN , DC and anti-tumor immunity
Stefani Spranger, Boston, MA, USA
12.10 - 12.40
02.02. Immunocytokines
Dario Neri, Zurich, Switzerland
12.40 - 13.10
02.03. Targeting TBK1 to overcome resistance to immunotherapy
Russel W. Jenkins, Boston, MA, USA
​
13.10 - 13.40 Satellite Symposium
Click HERE to read more
​
13.40 - 15.00 Lunch & Poster Viewing
​
15.00 - 17.00 Plenary Session 3: Exploiting B Cells and Other Cell Types
Chair: Andrea Schmidts, Munich, Germany & Mascha Binder, Basel, Switzerland
​
15.00 - 15.30
03.01. iPSC-derived strategies for cancer immunotherapy
Maria Themeli, Amsterdam, The Netherlands
15.30 - 16.00
03.02. Myeloid ontogeny and metabolic rewiring in the tumor microenvironment
Serena Vegna, Amsterdam, The Netherlands
16.00 – 16.15
03.03. Tertiary lymphoid structures in pancreatic cancer resemble lymphoid follicles in secondary lymphoid organs as sites for
initiation and maintenance of anti-tumor T- and B-cell responses
Kerstin Wennhold, Cologne, Germany
16.15 – 16.30
03.04. Targeted disruption of tumor-borne GDF-15-mediated immunoresistance restores immune checkpoint inhibitor activity in last-line cancer patients
Christine Schuberth-Wagner, Planegg-Martinsried, Germany
16.30 – 16.45
03.05. DSP216 blocks HLA-G and CD47 signaling toward immune cells and restores anti-cancer activity
Lisa Jacob, Groningen, The Netherlands
16.45 – 17.00
03.06. Cancer-specific oral microbiotherapy for cancer immunotherapy
Chong-xian Pan, Boston, MA, USA
​
17.00 - 18.00 Plenary Session 4: ITOC10 Keynote Lecture
Chair: Christoph Zielinski, Vienna, Austria
​
04.01. The role of the Homo sapiens in the emergence and the management of the climate crisis
Dr. Philipp Blom, Vienna, Austria
​
18.00 - 20.00 Networking Event and Poster Viewing (at the venue)
​
Friday, March 22, 2024
​
08.15 – 08.30 Late breaking abstract: Controversies in Immuno-Oncology
Chair: Michael von Bergwelt, Munich, Germany & Sebastian Kobold, Munich, Germany
​
08.15 – 08.30
LB 01.01. Targeting IL-2 activated lymphocytes against otherwise incurable multi-drug resistant hematologic malignancies
potentially competing with CAR-T cells
Shimon Slavin, Tel Aviv, Israel
​
08.30 – 09.30 Plenary Session 5: Microbiome
Chair: Hendrik Poeck, Regensburg, Germany & Caroline Alves Costa Silva, Villejuif, France
​
08.30 – 09.00
05.01. Microbiota modulation of cancer immunotherapy
Caroline Alves Costa Silva, Villejuif, France
09.00 – 09.30
05.02. Impact of microbiome on CAR T cell efficacy
Christoph Stein-Thöringer, Tübingen, Germany
​
09.30 – 10.30 Plenary Session 6: Pro & Contra Sessions: Adjuvant vs Neoadjuvant IO Treatment
Chair: Christoph Zielinski, Vienna, Austria & Lucie Heinzerling, Munich, Germany
​
09.30 – 10.00
06.01. Pro-Adjuvant
Alexander Eggermont, Utrecht, The Netherlands
10.00 – 10.30
06.02. Pro-Neoadjuvant
Christian Blank, Leiden, The Netherlands
​
10.30 – 11.00 Coffee Break
​
11.10 – 12.30 Plenary Session 7: Combination Therapies
Chair: Chong-Xia Pan, Boston, MA, USA & Tanja De Gruijl, Amsterdam, The Netherlands
​
11.00 – 11.30
07.01. Intradermal CpG/tilsotolimod treatment in pT3-4 cN0M0 melanoma: efficacy update of the randomized INTRIM trial
Tanja de Gruijl, Amsterdam, The Netherlands
11.30 – 12.00
07.02. Tuning bispecific antibody application and rationale combinations for optimal therapies
Marion Subklewe, Munich, Germany
12.00 – 12.30
07.03. The role of TLS in the response to IO agents
Antoine Italiano, Bordeaux, France
​
12.30 – 14.30 Lunch & Poster Viewing
​
14.30 – 15.15 Plenary Session 8: ITOC10 Lifetime Achievement Award presented to Prof. Dr. Andrea Schietinger
Chair: Sebastian Kobold, Munich, Germany & Michael von Bergwelt, Munich, Germany
​
08.01. Deciphering mechanisms of T cell exhaustion
Andrea Schietinger, New York, NY, USA
​
15.15 - 16.30 Plenary Session 9: Immuno-Monitoring
Chair: Michael Bergmann, Vienna, Austria & Eric Tartour, Paris, France
​
15.15 – 15.45
09.01. Multidimensional dissection of tumor-immune interaction
Rebekka Schneider-Kramann, Aachen, Germany
15.45 - 16.15
09.02. CODEXing the TME
Christian Schürch, Tübingen, Germany
16.15 - 16.30
09.03. Characterization of T cell specificity and exercise-induced dynamics of soluble immunological markers before and after high-intensity aerobic exercise (INHALE)
Katharina Leuchte, Herlev, Denmark
​
16.30 - 17.00 Coffee Break
17.00 - 18.00 Plenary Session 10: Young Researcher Session (from submitted abstracts)
Chair: Louisa von Baumgarten, Munich, Germany & Stefan Endres, Munich, Germany
​
17.00 – 17.15
10.01. Prostanoid-insensitive chimeric antigen receptor modified T cells mediate therapeutic efficacy in solid cancer models
Janina Dörr, Munich, Germany
17.15 – 17.30
10.02. Combined anti-angiogenic treatment to increase intratumoral persistence of CAR T-cells in lung cancer brain metastases
Constantin Eberle, Munich, Germany
17.30 – 17.45
10.03. Long lasting alterations of the immunophenotype and cytokine signature of DLBCL survivors results in persisting immune dysfunction
Giulia Benintende, Erlangen, Germany
17.45 – 18.00
10.04. Spatial transcriptomics identifies metabolic dysregulation as a key driver of T cell exclusion in esophageal adenocarcinoma
Jasper Sanders, Amsterdam, The Netherlands
​
18.00 - 19.00 Poster Viewing with Presenters
​
20.00 ITOC10 Conference Dinner
Saturday, March 23, 2024
​
08.00 – 09.00 Plenary Session 11: Reaching New Grounds in Cellular Therapies
Chair: Michael von Bergwelt, Munich, Germany & Fabian Müller, Erlangen, Germany
​
08.00 – 08.30
11.01. CD19 CAR T in B cell driven auto-immune disease
Fabian Müller, Erlangen, Germany
08.30 – 09.00
11.02. TIL have come back of age in Melanoma
Troels Holz Borch, Herlev, Denmark
​
09.00 – 10.30 Plenary Session 12: Cell therapies in Hematologic Oncology
Chair: Marion Subklewe, Munich, Germany & Ulrich Jäger, Vienna, Austria
​
09.00 – 09.30
12.01. Leveraging metabolites to boost CAR T cell activity in hematology
Hendrik Poeck, Regensburg, Germany
09.30 – 10.00
12.02. Cellular immunotherapy beyond CAR T cells in hematology
Jianzhu Chen, Cambridge, MA, USA
10.00 – 10.30
12.03. New approaches for cellular therapies in AML
Saar Gill, Philadelphia, PA, USA
​
10.30 – 11.00 Coffee Break
​
11.00 – 12.30 Plenary Session 13: Cell Therapies in Solid Oncology
Chair: Maik Luu, Würzburg, Germany & Johanna Olweus, Oslo, Norway
​
11.00 – 11.30
13.01. CAR-T in prostate cancer
Vivek Narayan, Philadelphia, PA, USA
11.30 – 12.00
13.02. Engineering cytokine functionalities in CAR T cells
Saul Priceman, Duarte, CA, USA
12.00 – 12.15
13.03. Empowering TCR-T cells for adoptive therapy for solid tumor through engineering with PD-1-based chimeric
costimulatory switch proteins
Elfriede Noessner, Munich, Germany
12.15 – 12.30
13.04. Improving the efficacy of TCRtg T cell therapy for solid tumors with mRNA-based vaccination
Janna Krueger, Tübingen, Germany
12.30 – 12.45
13.05. A Novel Approach for Neoantigen Discovery from Splicing Factor Mutated Cancers
Teryn Mitchell, New York, NY, USA
​
12.45 – 13.15 Plenary Session 14: Best Poster Awards & Closing Remarks
Chair: Tanja De Gruijl, Amsterdam, The Netherlands & TBA
​
13.15 – 14.15 Lunch & Farewell
​
​